Divisadero Street Capital Management LP Decreases Stake in Bioventus Inc. $BVS

Divisadero Street Capital Management LP reduced its holdings in shares of Bioventus Inc. (NASDAQ:BVS) by 35.6% during the third quarter, HoldingsChannel reports. The firm owned 695,517 shares of the company’s stock after selling 385,116 shares during the period. Divisadero Street Capital Management LP’s holdings in Bioventus were worth $4,653,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Nantahala Capital Management LLC raised its position in Bioventus by 28.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company’s stock worth $34,959,000 after buying an additional 1,155,192 shares during the last quarter. Kent Lake PR LLC purchased a new stake in shares of Bioventus during the 2nd quarter valued at about $2,317,000. Kennedy Capital Management LLC raised its holdings in shares of Bioventus by 219.6% during the third quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company’s stock valued at $3,088,000 after purchasing an additional 317,157 shares during the last quarter. Segall Bryant & Hamill LLC lifted its position in Bioventus by 468.9% during the second quarter. Segall Bryant & Hamill LLC now owns 281,849 shares of the company’s stock valued at $1,866,000 after purchasing an additional 232,302 shares during the period. Finally, Two Sigma Investments LP bought a new position in Bioventus during the third quarter valued at approximately $1,372,000. 62.94% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total value of $105,480.00. Following the transaction, the director owned 44,997 shares of the company’s stock, valued at $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BVS has been the subject of a number of research analyst reports. Barrington Research lifted their target price on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Weiss Ratings restated a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Finally, Craig Hallum increased their target price on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $14.25.

Bioventus Trading Up 0.2%

Shares of Bioventus stock opened at $8.62 on Monday. Bioventus Inc. has a 1-year low of $5.81 and a 1-year high of $10.13. The company’s fifty day simple moving average is $8.25 and its 200-day simple moving average is $7.55. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19. The stock has a market capitalization of $716.75 million, a PE ratio of 26.12 and a beta of 0.78.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.22 by $0.02. The firm had revenue of $157.90 million during the quarter. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.